Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Heron Therapeutics (HRTX) Shares Outstanding (Weighted Average) (2016 - 2026)

Heron Therapeutics filings provide 16 years of Shares Outstanding (Weighted Average) readings, the most recent being $189.6 million for Q1 2026.

  • On a quarterly basis, Shares Outstanding (Weighted Average) rose 23.56% to $189.6 million in Q1 2026 year-over-year; TTM through Mar 2026 was $189.6 million, a 23.56% increase, with the full-year FY2025 number at $166.7 million, up 9.35% from a year prior.
  • Shares Outstanding (Weighted Average) hit $189.6 million in Q1 2026 for Heron Therapeutics, up from $166.7 million in the prior quarter.
  • In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $189.6 million in Q1 2026 to a low of $102.1 million in Q1 2022.
  • Median Shares Outstanding (Weighted Average) over the past 5 years was $151.2 million (2024), compared with a mean of $139.5 million.
  • Biggest five-year swings in Shares Outstanding (Weighted Average): soared 37.49% in 2023 and later rose 1.4% in 2025.
  • Heron Therapeutics' Shares Outstanding (Weighted Average) stood at $108.9 million in 2022, then rose by 26.87% to $138.1 million in 2023, then rose by 10.36% to $152.4 million in 2024, then rose by 9.35% to $166.7 million in 2025, then increased by 13.76% to $189.6 million in 2026.
  • The last three reported values for Shares Outstanding (Weighted Average) were $189.6 million (Q1 2026), $166.7 million (Q4 2025), and $159.5 million (Q3 2025) per Business Quant data.